TAS::75 0849::TAS THE GOAL OF THIS PROJECT IS TO DEVELOP STC TRASTUZUMAB, A GEN

该项目的目标是开发STC曲妥珠单抗，这是Herceptin的仿制版本。曲妥珠单抗是一种针对HER2蛋白的单抗，在20%-25%的乳腺癌患者中过度表达。由于开赫赛汀的成本非常高，这种药物的仿制药将使更广泛的人群更容易负担得起癌症治疗，并降低政府资助的医疗项目的成本负担。 STC Biologics Inc.在应对反向工程曲妥珠单抗的技术挑战方面具有得天独厚的优势，因为其药物开发平台提供了对重组蛋白质翻译后修饰的快速有效分析。

The goal of this project is to develop STC trastuzumab, a generic version of Herceptin. Trastuzumab is a monoclonal antibody made against the HER2 protein that is overexpressed in 20-25% of patients with breast cancer. Because of very high cost associated with prescribing Herceptin, a generic version of this drug would make cancer treatment more affordable to a wider segment of the population and lower the cost burden on government-sponsored healthcare programs. STC Biologics Inc. is uniquely positioned to address the technical challenge of reverse engineering trastuzumab as its drug development platform offers rapid and efficient analysis of post-translational modification of recombinant proteins.